RNAi-Based Treatment for Neovascular Age-Related Macular Degeneration by Sirna-027
Peter K Kaiser, RC Andrew Symons, Syed Mahmood Shah, Edward J Quinlan, Homayoun Tabandeh, Diana V Do, Gail Reisen, Jennifer A Lockridge, Brian Short, Roberto Guerciolini, Quan Dong Nguyen
American Journal of Ophthalmology | ELSEVIER SCIENCE INC | Published : 2010
SUPPORTED BY SIRNA THERAPEUTICS, INC, SAN FRANCISO, CALIFORNIA. THE COLE EYE INSTITUTE, THE EMPLOYER OF DR Kaiser, and the Johns Hopkins University, the employer of Drs Symons, Shah, Quinlan, Do, and Nguyen, have received research grant support from Allergan and Sirna Therapeutics, Inc. Drs Kaiser and Quinlan served on the Scientific Advisory Board of Allergan. Drs Lockridge and Guerciolini and Ms Reisen were employees of Sirna Therapeutics, Inc. Dr Short is an employee of Allergan, Inc. Involved in design and conduct of the study (P.K.K., R.G., Q.D.N.); Collection, management, analysis, and interpretation of the data (P.K.K., R.C.A.S., S.M.S., E.J.Q., H.T., D.V.D., OR., J.A.L., B.S., R.G., Q.D.N.); and Preparation, review, or approval of the manuscript (P.K.K., S.M.S., E.J.Q., H.T., D.V.D., OR., J.A.L., B.S., R.G., Q.D.N.). The study received institutional review board approval at both the Wilmer Eye Institute, Johns Hopkins University, and the Cole Eye Institute, Cleveland Clinics. All study sites were compliant with the Health Insurance Portability and Accountability Act of 1996. Before determination of eligibility for enrollment, patients provided written, informed consent for study participation. The study was posted to http://www.clinicaltrials.gov (identified no. NCT00363714).